What is the mechanism of action of this treatment?

The most common treatments for Long COVID Syndrome, particularly those similar to BrainHQ, focus on cognitive rehabilitation and neuroplasticity. BrainHQ is a cognitive training program designed to enhance cognitive functions such as memory, attention, and executive function through targeted exercises. These exercises stimulate neural pathways and promote brain plasticity, which can help mitigate cognitive deficits experienced by Long COVID patients. This is crucial for patients as it addresses persistent cognitive symptoms, potentially improving their quality of life and functional independence.

What side effects are associated with this type of intervention?

Common treatments for Long COVID Syndrome, particularly cognitive training programs like BrainHQ, generally have minimal side effects. These programs aim to improve cognitive function through structured exercises and are typically well-tolerated. However, some individuals may experience temporary fatigue or frustration due to the mental effort required. Other treatments for Long COVID, such as physical rehabilitation and psychological therapies, may also cause mild side effects like muscle soreness, emotional distress, or anxiety. It is important to monitor these symptoms and consult with healthcare providers to tailor the treatment plan accordingly.

What prior FDA approvals exist?

There are no specific FDA-approved treatments for Long COVID Syndrome mentioned in the provided context. However, BrainHQ, a cognitive training program, is being studied for its potential benefits in improving cognitive dysfunction associated with Long COVID. This program is commercially available, accessible, and has been effective in other studies of cognitive dysfunction, such as aging and traumatic brain injury.

What other types of research exist?

Promising alternatives to BrainHQ for Long COVID Syndrome patients include PASC CoRE and transcranial direct current stimulation (tDCS). Both have shown potential in improving cognitive function in other clinical settings and may offer additional benefits beyond BrainHQ alone.

← Back to Search

Behavioural Intervention

Cognitive Rehabilitation for Long COVID

N/A

Waitlist Available

Research Sponsored by Duke University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, eoi (day 70), end of study (eos) (day 160)

Awards & highlights

Summary

This trial tests different treatments to help people who have cognitive problems after COVID-19. It includes an online brain training program, specialized rehab exercises, and mild electrical brain stimulation. The goal is to see if these methods can improve attention and executive function. Mild electrical brain stimulation has been used in the rehabilitation of cognitive function in various neurological disorders since 2000.

Who is the study for?

This trial is for individuals with Long COVID who experience cognitive issues like trouble with thinking or attention. Participants must meet the broader RECOVER-NEURO protocol criteria and cannot have metal objects in their head/neck, skin conditions near tDCS stimulation sites, or any other risks as determined by the investigator.

What is being tested?

The study tests BrainHQ exercises alone, combined with PASC CoRE (a cognitive rehabilitation program), or paired with active/sham tDCS (transcranial direct current stimulation) to see if they improve cognition in Long COVID patients compared to standard activities.

What are the potential side effects?

Potential side effects may include discomfort at the electrode site from tDCS, mild headaches, itching under electrode pads during stimulation, and fatigue. Side effects are generally minimal for BrainHQ exercises.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, eoi (day 70), end of study (eos) (day 160)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, eoi (day 70), end of study (eos) (day 160)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, eoi (day 70), end of study (eos) (day 160) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Change in Everyday Cognition 2 (ECog2)

Change in PROMIS-cognitive function - short form 8a (PROMIS-Cog) total score

Trial Design

5Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: BrainHQ + PASC CoREExperimental Treatment2 Interventions

BrainHQ plus 9 group sessions at 1.5 hr/session and 3 individual sessions at 1 hr/session

Group II: BrainHQExperimental Treatment1 Intervention

5 sessions/week at 30 min/session

Group III: Brain HQ + tDCS-activeExperimental Treatment2 Interventions

2.0 mA stimulation delivered for 30 min during each BrainHQ session

Group IV: BrainHQ Active ComparatorActive Control1 Intervention

5 sessions/week at 30 min/session

Group V: Brain HQ + tDCS-shamPlacebo Group2 Interventions

Inactive stimulation delivered for 30 min during each BrainHQ session

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for Long COVID Syndrome, particularly those similar to BrainHQ, focus on cognitive rehabilitation and neuroplasticity. BrainHQ is a cognitive training program designed to enhance cognitive functions such as memory, attention, and executive function through targeted exercises. These exercises stimulate neural pathways and promote brain plasticity, which can help mitigate cognitive deficits experienced by Long COVID patients. This is crucial for patients as it addresses persistent cognitive symptoms, potentially improving their quality of life and functional independence.

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor

2,424 Previous Clinical Trials

3,065,756 Total Patients Enrolled

Kanecia Zimmerman, MD PhDStudy ChairDuke University

2 Previous Clinical Trials

1,228 Total Patients Enrolled

Daniel Laskowitz, MD MHSStudy ChairDuke University

1 Previous Clinical Trials

328 Total Patients Enrolled

Media Library

BrainHQ (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05965739 — N/A

Long COVID Syndrome Research Study Groups: Brain HQ + tDCS-sham, BrainHQ, BrainHQ + PASC CoRE, Brain HQ + tDCS-active, BrainHQ Active Comparator

Long COVID Syndrome Clinical Trial 2023: BrainHQ Highlights & Side Effects. Trial Name: NCT05965739 — N/A

BrainHQ (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05965739 — N/A

~164 spots leftby Sep 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.